Welcome to the future of precision medicine


How will protein biomarkers influence the future of global healthcare?

Clinical care for the most part still adheres to a one-size-fits-all approach, based on strategies that have been developed for the “average” person, with less consideration of individual differences. The move to more stratified medicine that delivers the right treatment to the right patient at the right time represents the next great movement for global healthcare, but also a colossal challenge for science. Protein biomarker strategies will be key to these developments, helping to us to better understand the biology of disease, to develop new, better and more targeted drugs, and to provide them to the right patients in a more stratified and effective manner.

"Precision Proteomics to Drive Personalized Medicine" is an invitation-only symposium that will bring together some of the leading researchers in this field, to present their work to an invited audience of like-minded colleagues, and to stimulate a creative discussion on recent progress and future challenges. Welcome to Stockholm!
Professor Mathias Uhlén

Speaker roster

Mathias Uhlén, PhD

Professor at the Royal Institute of Technology (KTH), Stockholm, Sweden. With over 650 publications to date, his research is focused on protein science, antibody engineering and precision medicine and ranges from basic research to clinical applications in cancer, infectious diseases, cardiovascular diseases, autoimmune diseases and neurobiology. Since 2003, he has led an international effort to systematically map the human proteome with antibodies and to create an open source knowledge-based resource called the Human Protein Atlas (www.proteinatlas.org). Based on the Protein Atlas effort (Uhlen et al, Science, 2015), he has launched a new wellness profiling effort in which individuals have been monitored every three months and analyzed using whole genome sequencing, cell analysis, proteomics, metabolomics and microbiome analysis. Professor Uhlén will host the symposium and deliver the plenary lecture.

Eric Fauman, PhD

Senior Scientific Director and Head, Computational Target Validation at Pfizer. Dr. Eric Fauman received his PhD from the University of California, San Francisco for work on protein structure determination by X-ray crystallography.  He continued his training with post-doctoral work at the University of Michigan, solving the first crystal structure of a cell cycle phosphatase, CDC25A. For the past 20 years, Dr. Fauman has been a computational biologist at Pfizer, working with disease biologists to identify and prioritize drug targets to address unmet medical needs.  He currently leads a team of computational biologists and geneticists dedicated to Computational Target Validation working across multiple disease areas. Dr. Fauman is particularly interested in the interpretation of genome-wide association studies (GWAS) in terms of the underlying biological processes and how this information can be used to understand diseasepathophysiology.

Adam Butterworth, PhD

Lecturer in Cardiovascular Epidemiology at Cambridge University. Following training in Genetics at the University of Cambridge and Genetic Epidemiology at the University of Sheffield, Adam completed a PhD in meta-analysis of genetic association studies of coronary heart disease at the University of Cambridge.  This research was carried out jointly with the PHG Foundation, the MRC Biostatistics Unit, and the Cardiovascular Epidemiology Unit. Since his PhD, Adam has worked in the Cardiovascular Epidemiology Unit, initially as a post-doctoral Research Associate, and since 2012 as a University Lecturer. As well as leading a Genetic Epidemiology team, Adam also oversees the Unit’s PhD students. Adam is the Scientific Coordinator of the EPIC-Heart/EPIC-CVD study, which is a pan-European study of incident coronary disease and stroke including participants from 23 centres across 10 European countries.

Robert Gerszten, MD, PhD

Professor of Medicine at Harvard Medical School and Senior Associate Member of the Broad Institute. Dr Gerszsten is Director of Clinical and Translational Research for the MGH Heart Center. He graduated from the Johns HopkinsUniversity School of Medicine, did his residency at the University ofPennsylvania, and his clinical fellowship in Cardiology at MGH.  Over the past decade, the Gerszten laboratory has built a nationally recognized program in translational research, integrating emerging metabolomic and proteomic approaches towards the identification of novel disease pathways and biomarkers.  An area of particular focus is the application of these tools to identify those most likely to benefit from clinical interventions in cardiometabolic diseases. His highly interactive program collaborates across a spectrum of institutions, from the Broad Institute to the Framingham Heart Study and the TIMI Study Group.

Stefan Blankenberg, MD, PhD

Professor of medicine at the University Heart Center, Hamburg. After studying medicine in Mainz, Frankfurt and New York, he got his MD thesis in 1998. In September 2005, he was nominated as full professor of medicine and faculty member of the Johannes Gutenberg University,Mainz, becoming leading senior physician and deputy director of the Department of Medicine there in 2007. Professor Blankenberg was appointed Director of the Clinic for General and Interventional Cardiology, at the University Heart Center, Hamburg in 2011. He has received numerous awards from institutions such as the German Society of Cardiology & the European Society of Cardiology, amongst many others. His research is focused on individualized cardiovascular medicine with particular focus on acute coronary syndrome and heart failure. Dr. Blankenberg has published numerous papers in journals like NEJM, Nature Genetics, JAMA, Circulation, JACC and European Heart Journal.

Faiez Zannad, MD, PhD

Professor of Therapeutics and Cardiology at INSERM. He is at the Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the department of Cardiovascular Disease of the Academic Hospital (CHU) in Nancy and the Director of the Clinical Investigation Centre (Inserm-CHU) of Nancy since 1995. He entered the European Society of Cardiology (ESC) in 1996 and is past Chairman of the European Society of Cardiology (ESC) Working group on Pharmacology and Drug Therapy and past-President of the French Society of Hypertension. He is the Principal investigator and Member of Steering committees of major large-scale trials in human cardiology (RALES,VALIANT, CIBIS, CAPRICORN, EPHESUS, EMPHASIS-HF). He has served as Co-Editor-in-Chief for Fundamental and Clinical Pharmacology, the official journal of the European Pharmacology Societies Federation (EUPHAR). He chairs and organises annual international meetings on CardioVascular Clinical Trials (CVCT) and on Biomarkers in Heart Failure.

Agneta Siegbahn, MD, PhD

Senior Professor of Clinical Coagulation Science at Uppsala University and founder and Platform Director of the Clinical Biomarkers Facility at SciLifeLab Uppsala. She obtained her PhD from Uppsala University and has published over 220 original scientific papers and numerous review articles and book chapters. In addition to this major contribution to the CVD literature, she has also played an important role in the increased use of
protein biomarker discovery in academic and clinical research in the Nordic region, setting up and directing the Clinical Biomarkers Facility at SciLifeLab in Uppsala. Among other things, this facility has enabled many Swedish scientists and clinicians to use a proteomics discovery approach in their research, offering Olink’s biomarker panels on a service basis. Professor
Siegbahn currently heads the Clinical Coagulation and Inflammation Science
group at the Department of Medical Sciences.

Jonas Halfvarson, MD, PhD

Associate Professor at Örebro University & Consultant Gastroenterologist at Örebro University Hospital, Sweden. He graduated as MD at Uppsala University, Sweden, before training in gastroenterology at Örebro University Hospital. He obtained his PhD, entitled ‘Inflammatory bowel disease in twins; Studies of genetics and environmental factors’ in 2004. His research focuses on biomarkers in IBD, both from a clinical and from a mechanistic perspective, the latter using twin studies to disentangle the influence of genetic predisposition and exposure to environmental factors. He has published over 100 peer-reviewed papers, as well as contributed to several books on IBD. He has served as vice director for the Swedish national PhD and Postdoctoral program for translational gastroenterology and heads the taskforce for genetics and pathophysiology at the Swedish Organisation for the Study of IBD.

Lars Klareskog, MD, PhD

Professor of Rheumatology at the Karolinska Institute, Stockholm. Dr. Klareskog has had a longstanding interest in the Genetics and Immunology of Rheumatoid Arthritis. He is a medical graduate of Uppsala University where he became Professor at the Clinical Immunology Department in 1990. In 1993, he became  Professor of rheumatology at Karolinska Institute. He is a member of the NobelAssembly and a past member of the Nobel Committee and has acted as the Chairman of the Scientific Board of the Swedish Rheumatism Association since 1997. He has received wide international acclaim for his research in rheumatology and serves on the editorial boards of numerous journals including amongst many, Arthritis & Rheumatism and Current Opinion in Rheumatology.  Dr. Klareskog has published over 300 articles in leading journals including Nature Genetics, New England Journal of Medicine and Nature.

Tomas Olsson

Professor of neurology at Karolinska Institute (KI). He received his MD from University of Linköping, Sweden in 1977 and went on to complete his PhD in Medical Sciences in 1980. He was appointed as Professor of Molecular Medicine in 1995, and since 2008 has held the post of Professor in Neurology at KI. Prof. Olsson is member of the Nobel Assembly, and its Chairman in 2017. He is a member and co-founder of the Swedish Multiple Sclerosis Society and a member of multiple international MS societies. Prof. Olsson is a board member and co-founder of the European school of Neuroimmunology (ESNI), member of the international scientific board of the international congress of Neuroimmunology (ISNI), former executive board member of the international scientific board of the European committee for the treatment of MS. (ECTRIMS) and member of the International Multiple Sclerosis Genetics Consortium (IMSGC).

Henrik Zetterberg

Professor of neurochemistry at the University of Gothenburg, Sweden. He is also professor at University College London, United Kingdom, and a clinical chemist at the Sahlgrenska University Hospital in Gothenburg. Prof. Zetterberg is also head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg. His main research focus and clinical interest is fluid biomarkers for central nervous system disorders including Alzheimer’s disease, for which he has developed new diagnostic tests. He has published more than 800 scientific articles and previously received the Erik K. Fernström Prize for young scientists and the Inga Sandeborg Prize for research on Alzheimer’s disease.

Ulf Gyllensten

Professor of Medical Molecular Genetics at the Department of Immunology, Genetics and Pathology, Uppsala University. He has over 250 peer-reviewed publications and has held many prestigious academic positions, including the editorial boards of several international journals, the priority committees of the Swedish Medical Research Council and Swedish Cancer Society, Director of the world renowned Rudbeck Laboratory and currently, Scientific Director of the Science for Life Laboratory in Uppsala. Professor Gyllensten also holds multiple biotechnology patents, is co-founder of the Swedish biotech companies Dechipher Genetics AB and Quantovir AB and has acted as consultant for both Perkin-Elmer and Roche Molecular Systems.

Erik Ingelsson, MD, PhD

Professor of Medicine at Stanford University. His research area is cardiovascular medicine with a focus on metabolic disturbances such as obesity and insulin resistance, and their role in the development of cardiovascular disease. He is combining large population-based studies with functional in vivo and in vitro studies in a translational framework. Dr. Ingelsson obtained his MD (2000) and PhD (2005) at Uppsala University, Sweden.  He was appointed Professor of Cardiovascular Epidemiology in 2010 at the Karolinska Institute and from 2013-2016, he was a Professor of Molecular Epidemiology at Uppsala University. He was also a Visiting Professor at the Wellcome Trust Centre for Human Genetics at University of Oxford in 2012-2015 and since May 2016, is Professor of Medicine at Stanford University. Professor Inglesson will chair the symposium.


Practical information

Venue – Nobel Forum

This is the buildiing where the Nobel Secretariat carries on its daily work. It is also here that the Nobel Committee announces the year’s Laureate in Physiology or Medicine. With the Nobel Forum, the Karolinska Institute has also gained a meeting place for scientists from all over the world. See more information here

Nobel Forum
Nobels väg 1
17165 Solna

Experience Stockholm

If you are coming to the symposium from out of town and have the opportunity, there is no better time to explore the beautiful city of Stockholm than Midsummer week, when the days stretch out until late into the evening. Click the link below to find the top ten things to do in Stockholm!
Official City Guide:
Can we help you with something?
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
About the conference
"Precision Proteomics to Drive Personalized Medicine" is an international one-day symposium, hosted by Professor Mathias Uhlén and sponsored by Olink Proteomics. The meeting will focus on how protein biomarker-based strategies can influence and drive the development of a more stratified approach to healthcare, and help to realize the potential of "precision medicine". As well as featuring presentations from some of the world's leading researchers in this field, the event aims to provide a forum where academia and industry can exchange views and forge collaborations, interactions that are essential for the future of global healthcare. Attendance is strictly by invitation only, but if you have any questions or comments about this or future events, please use the simple form above.